Better Therapeutics, Inc.
BTTX · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $8 | $18 |
| % Growth | – | -100% | -55.6% | – |
| Cost of Goods Sold | $2,729 | $1,619 | $682 | $898 |
| Gross Profit | -$2,729 | -$1,619 | -$674 | -$880 |
| % Margin | – | – | -8,425% | -4,888.9% |
| R&D Expenses | $16,440 | $19,436 | $2,978 | $2,290 |
| G&A Expenses | $14,843 | $8,788 | $2,455 | $2,197 |
| SG&A Expenses | $21,822 | $11,124 | $2,671 | $2,603 |
| Sales & Mktg Exp. | $6,979 | $2,336 | $216 | $406 |
| Other Operating Expenses | -$2,729 | -$1,619 | $0 | $0 |
| Operating Expenses | $35,533 | $28,941 | $5,649 | $4,893 |
| Operating Income | -$38,262 | -$30,560 | -$6,323 | -$5,773 |
| % Margin | – | – | -79,037.5% | -32,072.2% |
| Other Income/Exp. Net | -$1,491 | -$9,928 | $89 | -$11 |
| Pre-Tax Income | -$39,753 | -$40,488 | -$6,234 | -$5,784 |
| Tax Expense | $7 | -$153 | $153 | $0 |
| Net Income | -$39,760 | -$40,335 | -$6,387 | -$5,795 |
| % Margin | – | – | -79,837.5% | -32,194.4% |
| EPS | -1.69 | -1.71 | -1.04 | -0.25 |
| % Growth | 1.2% | -64.4% | -316% | – |
| EPS Diluted | -1.69 | -1.71 | -1.04 | -0.25 |
| Weighted Avg Shares Out | 23,557 | 23,603 | 7,558 | 23,600 |
| Weighted Avg Shares Out Dil | 23,558 | 23,603 | 7,558 | 23,600 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $0 | $0 | $0 |
| Interest Expense | $1,491 | $185 | $100 | $11 |
| Depreciation & Amortization | $53 | $1,619 | $75 | $72 |
| EBITDA | -$38,209 | -$38,684 | -$6,059 | -$5,701 |
| % Margin | – | – | -75,737.5% | -31,672.2% |